基于1D CNN与XGBoost的恶意代码纹理检测

恶意代码数量已经呈现爆炸式增长,对于恶意代码的检测防护显得尤为重要.近几年,基于深度学习的恶意代码检测方法开始出现,基于此,提出一种新的检测方法,将恶意代码二进制文件转化为十进制数组,并利用一维卷积神经网络(1 Dimention Convolutional Neural Networks,1D CNN)对数组进行分类和识别.针对代码家族之间数量不平衡的现象,该算法选择在分类预测上表现良好的XGBoost,并对Vision Research Lab中的25个不同恶意软件家族的9458个恶意软件样本进行了实验.实验结果表明,所提的方法分类预测精度达到了97％.     

煤矸石粉/聚酯纤维沥青混合料盐冻损伤研究EI北大核心CSCD

针对煤矸石粉替代率50%、聚酯纤维掺量0.4%的沥青混合料,开展盐冻耦合作用(NaCl溶液质量分数为0%、7.0%、13.0%、26.5%,冻融循环次数为0、2、4、6、8)下的半圆弯曲(SCB)试验,分析了盐冻耦合作用对SCB试件内部损伤劣化过程的影响.结果表明:NaCl溶液质量分数为13.0%、冻融循环为8次时,盐冻耦合作用对沥青混合料的侵蚀破坏作用最强,试件内部损伤最严重;在煤矸石粉与矿粉质量比为1∶1、聚酯纤维掺量为0.4%的条件下,沥青混合料能够形成高黏性、致密、厚实的沥青膜以及由纤维形成的三维网状结构,从而显著降低盐冻侵蚀对沥青混合料的损伤.通过Poly2D模型对SCB试件的极限拉应力损伤量进行拟合,拟合系数为0.944.     

Optical design of the Lyman alpha based beam emission spectroscopy(LAB)diagnostic on the HL-2A tokamak

In this article, we present the optical design of a novel diagnostic on the HL-2 A tokamak, i.e. the20-channel edge Lyman-alpha beam emission spectroscopy, which is a promising solution for edge density turbulence research on tokamaks, as it offers the possibility of density fluctuation measurement with a 3.3 mm spatial resolution while maintains a high temporal resolution of1 μs. The optical path, including the reflective collection optics, the high-dispersion spectrometer, and the linear detector array, is carefully optimized to obtain a good image quality and a high throughput. The maximum root mean square radius of the collection optics is 64 μm.The detected photon flux is estimated to be about 10~(11) photons/s/channel.     

盾构隧道施工物料无人运输发展现状及关键技术

盾构隧道施工物料无人运输有助于提升运输效率、降低运输成本、减少运输安全事故率。与公路汽车无人驾驶、港口车辆无人驾驶、轨道交通无人驾驶等逐步成熟的无人驾驶技术不同，在隧道场景下实施施工物料无人运输存在运输物料种类繁多、运输调度困难、地下定位信号拒止、狭窄车道频繁会车、行车路面工况复杂、地上地下联动响应慢等诸多挑战。从实现盾构隧道施工物料无人运输的关键问题分析入手，综述当前盾构隧道施工物料运输方式、运输需求、无人运输发展现状及存在的挑战，提出盾构隧道施工物料无人运输的五大关键技术：多种类物料智能货控能效管理技术，无人化垂直装卸门机控制技术，多传感器融合同步定位与地图构建技术，隧道复杂环境路径规划与自主避障技术，隧-地一体化联动响应的高可靠性无线通信技术。     

Synergistic effect of high-intensity ultrasound and β-cyclodextrin treatments on browning control in apple juice

This work evaluated the synergistic effects of combined high-intensity ultrasound (HIU) with β-cyclodextrin (β-CD) treatments on inhibiting browning of apple juice and explored the mechanism through simulation system. The combined treatment of 300 W HIU with 0.006 g mL⁻¹ β-CD had a synergistic impact on maintaining juice colour, resulting in a 39.06% reduction in browning degree, only a 36.64% decrease in total phenolic content, and a 17.82% reduction in PPO activity. The inhibition of enzymatic browning in simulated system revealed that HIU suppressed the enzyme (Polyphenol oxidase, PPO) and β-CD inhibited enzyme (PPO) and embedded substrate (polyphenol). The results of spectroscopic analysis showed that the particle-size distribution of PPO narrowed, the content of α-helix in the secondary structure increased, the fluorescence intensity increased, and the maximum wavelength was red-shifted after HIU and β-CD treatment. Changes in structure could further result in PPO activity loss. Hence, the combined treatment could synthetically alleviate the browning of apple juice.     

Porous Co3O4 column as a high-performance Lithium anode material

Journal of Porous Materials - Co3O4 has been widely investigated as a promising candidate anode material for lithium-ion batteries. We report on the porous Co3O4 column synthesized via a simple...     

New Insights into the Pathogenesis of Systemic Mastocytosis

Mastocytosis is a type of myeloid neoplasm characterized by the clonal, neoplastic proliferation of morphologically and immunophenotypically abnormal mast cells that infiltrate one or more organ systems. Systemic mastocytosis (SM) is a more aggressive variant of mastocytosis with extracutaneous involvement, which might be associated with multi-organ dysfunction or failure and shortened survival. Over 80% of patients with SM carry the KIT D816V mutation. However, the KIT D816V mutation serves as a weak oncogene and appears to be a late event in the pathogenesis of mastocytosis. The management of SM is highly individualized and was largely palliative for patients without a targeted form of therapy in past decades. Targeted therapy with midostaurin, a multiple kinase inhibitor that inhibits KIT, has demonstrated efficacy in patients with advanced SM. This led to the recent approval of midostaurin by the United States Food and Drug Administration and European Medicines Agency. However, the overall survival of patients treated with midostaurin remains unsatisfactory. The identification of genetic and epigenetic alterations and understanding their interactions and the molecular mechanisms involved in mastocytosis is necessary to develop rationally targeted therapeutic strategies. This review briefly summarizes recent developments in the understanding of SM pathogenesis and potential treatment strategies for patients with SM.